Reinforced by the immunohistochemical study of the in situ expression of ICs and their ligands in CRC sections, our results highlight the TIGIT/CD155 axis as the most likely to inhibit the majority of anti-tumor T responses. This evidence concerns the gene TIGIT and colorectal carcinoma.